Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Investor Presentation (December 2022)
16 slides from Alembic Pharmaceuticals's investor presentation, December 2022
Slide 1: Alembic Pharmaceuticals Limited Investor presentation – December 2022
Alembic Pharmaceuticals Limited Investor presentation – December 2022 BSE & NSE: APLLTD 1
Slide 2: Milestones
Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2009 Multiple divisions to address chronic therapies launched 2010 Pharmaceuticals business demerged from Alembic – APL
Slide 3: Financial Highlights
Financial Highlights INR Bn Particulars Q3 FY23 Q3 FY22 Growth YTD Dec'22 YTD Dec'21 Growth FY22 Net Sales 15.09 12.72 19% 42.46 38.9 9% 53.06 EBIDTA Pre R&D 3.68 3.98 -8% 9.83 12.13 -19% 16.40 Margin % 24% 31% 23% 31% 31% R&D 1.57 1.54 2% 5.86 4.89 20% 8.38 R&D % 10% 12% 14% 13% 16% EBIDTA Post R&D
Slide 4: Revenue snapshot – Q3 & YTD FY23
Revenue snapshot – Q3 & YTD FY23 INR Bn Key Highlights : Business Q2FY23 Q3FY23 Q3FY22 Y-o-Y Q-o-Q YTD Dec'22 YTD Dec'21 Y-0-Y Formulations India India Branded Business : India Branded Business recorded 5.49 5.45 4.88 12% -1% 15.73 14.78 6% US 4.18 4.32 3.93 10% 3% 12.18 11.09 10% 12% growth with to
Slide 5: India Business - Branded
India Business - Branded Revenue – Q3 FY23 INR Bn Revenue – Last 5 Years CAGR - 11% INR Bn 5.45 19.3 4.88 0.73 0.61 15.0 1.96 13.8 14.3 Vet 1.76 12.7 Acute Speciality 2.75 2.51 Q3FY22 Q3FY23 FY18 FY19 FY20 FY21 FY22 Marketing organization Key achievements ➢ 4700+ MRs ➢ India Branded Business recorde
Slide 6: India Business - Branded
India Business - Branded Top Brands with rank and MS% Prescription Business 957 Leading Brands Other Leading Brands Rank MAT Rank MAT 758 BRANDS MAT Dec Dec 22 BRANDS MAT Dec Dec 22 22 MS% 22 MS% AZITHRAL 1 31.6 ELATA 1 41.9 YTD Dec 21 TELLZY 5 4.9 VEHYCAL-XT 4 7.2 YTD Dec 22 220 223 WIKORYL 3 10.1
Slide 7: Therapy-wise Performance Q3 FY23
Therapy-wise Performance Q3 FY23 Q3 FY23 Q3 FY22 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share % Growth % Growth % Growth Share Growth % Growth % % (IPM) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Gynecology 12 3.2 31 27 13 2.7 15 13 Cardiology 11 1.8 10 8 8
Slide 8: Therapy-wise Performance 9M FY23
Therapy-wise Performance 9M FY23 9M FY23 9M FY22 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share % Growth % Growth % Growth Share Growth % Growth % % (IPM) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Gynecology 15 3.0 30 33 18 2.6 27 23 Cardiology 7 1.8 9 8 12
Slide 9: Animal Health Business
Animal Health Business Revenue - YTD Dec Revenue - YTD Dec for Major 5 brands CAGR - 26% INR Bn INR Bn CAGR 24% ↑ 1.34 1.09 0.84 0.67 Animal Health 2.19 1.16 FY20 FY23 FY20 FY21 FY22 FY23 Key achievements ➢ Leader in Hematinic Market covering Sharkoferrol Brand ➢ Leader in Anti Biotic Market coverin
Slide 10: US Generic
US Generic INR Bn Revenue – Q3 FY23 INR Bn Revenue – Last 5 Years CAGR - 16% 4.32 21.63 3.93 19.76 16.66 12.88 9.20 Q3FY22 Q3FY23 FY18 FY19 FY20 FY21 FY22 Approved ANDAs Injectable 6 Inhalation Derma 25 2 ➢ Well-established US front end having strong customer base ➢ 2 products launched in Q3FY23. Cu
Slide 11: Ex-US Generics
Ex-US Generics Revenue : Q3 FY23 INR Bn Revenue – Last 5 Years INR Bn CAGR - 28% 7% ↑ 2.06 7.79 7.75 1.93 4.94 4.97 Q3FY22 Q3FY23 ➢ Ex-US driven by partnership. Delivered impressive CAGR of 28% in last 5 years. 2.86 ➢ Presence in following key markets - Europe, Canada, Australia, Brazil and South Af
Slide 12: API
API Revenue : Q3 FY23 INR Bn Revenue – Last 5 Years INR Bn CAGR - 10% 3.26 9.55 9.39 1.98 7.71 7.08 6.51 Q3FY22 Q3FY23 ➢ Growth of 65% on QoQ basis is mainly on account of high off- take and better product mix in Q3. ➢ API Business posted growth of 11% on Sequential quarter basis. ➢ 4 USDMFs filed i
Slide 13: R&D Significant investments in building capabilities
R&D Significant 10.0 investments in building capabilities INR Bn ANDA – Accelerated filings & approvals 15.8% 37 Filing 8.0 14.0% Approval 13.1% 12.7% 29 30 29 12.4% 6.0 25 R&D Spend 23 20 21 18 19 4.0 8.4 11 Filings & 6.7 7 Approvals 6.5 R&D % of were 5.0 sales 2.0 4.1 contributed by acquisition of
Slide 14: State of the art facilities and infrastructure
State of the art facilities and infrastructure Last USFDA Location Dosage Form Audit International Generics F1 – Panelav General Oral Solids Mar’20* Oncology Oral Solids Jun’19* F2 – Panelav Oncology Injectables Oct’22* F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Ophthalmic Aug’22 F
Slide 15: Financials : Generating consistent returns
Financials : Generating consistent returns Revenue INR Bn EBIDTA Net Profit INR Bn INR Bn 53.93 53.06 16.31 11.78 46.06 39.35 12.13 8.29 31.31 10.53 # 8.75 6.65 # 5.84 6.42 4.13 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 CAGR - 14% CAGR - 13% CAGR - 13% EBIDTA margin
Slide 16: Thank you
Thank you Safe Harbour Agreement: Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and resu
Alembic Pharmaceuticals — Investor Presentation (December 2022) on 6ix